Diana West
Affiliations: | 2011 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Diana West"Mean distance: 8.43 | S | N | B | C | P |
Parents
Sign in to add mentor| Paul J. Hergenrother | grad student | 2011 | UIUC |
| Suzanne D. Conzen | post-doc | 2014-2016 | Chicago Medical School (Cell Biology Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| West DC, Kocherginsky M, Tonsing-Carter EY, et al. (2018) Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Kach J, Long TM, Selman P, et al. (2017) Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth. Molecular Cancer Therapeutics |
| Tonsing-Carter E, Bowie K, West D, et al. (2017) Abstract P3-05-09: Glucocorticoid receptor modulation affects ER+ breast cancer cell proliferation Cancer Research. 77 |
| West DC, Pan D, Tonsing-Carter EY, et al. (2016) GR and ER co-activation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Molecular Cancer Research : McR |
| West D, Hosfield D, Mayne C, et al. (2016) Abstract PD3-02: Second-generation selective glucocorticoid receptor modulators in triple-negative breast cancer Cancer Research. 76 |
| West DC, Qin Y, Peterson QP, et al. (2012) Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Molecular Pharmaceutics. 9: 1425-34 |
| Hsu DC, Roth HS, West DC, et al. (2012) Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1). Acs Combinatorial Science. 14: 44-50 |
| Lucas PW, Schmit JM, Peterson QP, et al. (2011) Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. Investigational New Drugs. 29: 901-11 |
| Peterson QP, Hsu DC, Novotny CJ, et al. (2010) Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Research. 70: 7232-41 |
| Peterson QP, Goode DR, West DC, et al. (2010) Preparation of the caspase-3/7 substrate Ac-DEVD-pNA by solution-phase peptide synthesis. Nature Protocols. 5: 294-302 |